Adolescent and Young Adult Clinical Trials

COG ACNS2021

A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

Patients must be greater than or equal to 3 years and less than 30 years at the time of study enrollment.

COG-ACNS2031: A Phase 3 Study of Sodium Thiosulfate for the Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy for Children with Medulloblastoma with Low-Risk Features

Age: ≥ 4 years and ≤ 21 years of age at the time of enrollment

A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas

Patients must be ≥ 3 years and < 30 years at the time of enrollment on screening.

AREN2231, Risk Adapted Treatment for Unilateral Favorable Histology Wilms Tumor (FHWT)

COG-AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Patients must be ≤ 30 years old at study enrollment.

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.

Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.

Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment. 

Stratum 2 of AGCT1531 (Low Risk, Stage I Non-Seminoma MGCT), has been temporarily closed to accrual as of December 17, 2024, pending an evaluation of patients currently enrolled on this study. 

COG ACNS2021

A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

Patients must be greater than or equal to 3 years and less than 30 years at the time of study enrollment.

Phase III Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Age ≥ 11 Years and ≤ 45 Years on the Date of Randomization

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

COG-ACCL1931: A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy

Age: ≥15 and <40 years at time of diagnosis.

AALL2131,  An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly Diagnosed Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia 

A Phase II Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Patients must be ≥1 Year and < 22 Years of Age at the Time of Enrollment.

COG AALL1821

A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse

COG-AAML1831: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

Patients must be less than 22 years of age at the time of study enrollment.

COG APAL2020SC

Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

Patients must be less than 22 years of age at the time of study enrollment.

Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB) A COG Groupwide Phase 3 Study

Patients must be ≤ 21 years of age at the time of study enrollment.

COG-AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Patients must be 5 to 60 years of age at the time of enrollment.

EAQ211: Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors

ALTE2131, Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.

Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.

Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment. 

Stratum 2 of AGCT1531 (Low Risk, Stage I Non-Seminoma MGCT), has been temporarily closed to accrual as of December 17, 2024, pending an evaluation of patients currently enrolled on this study. 

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.

Umbrella Long-Term Follow-Up Protocol

Only Available to Patients Already Enrolled on a COG Intervention Protocol.

COG-ANHL2121: Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

Age: 180 days- <22 years (at time of study enrollment).

A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

patients must be ≤ 30 years at the time of initial diagnosis with high-risk disease

COG AOST2031

A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

Patients must be < 50 years at the time of enrollment

COG- ARST2032: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma

Patients must be ≤ 21 years at the time of enrollment.